- Case report
- Open Access
Metastatic eccrine porocarcinoma: report of a case and review of the literature
© Marone et al; licensee BioMed Central Ltd. 2011
Received: 13 September 2010
Accepted: 16 March 2011
Published: 16 March 2011
Eccrine porocarcinoma (EPC) is a rare type of skin cancer arising from the intraepidermal portion of eccrine sweat glands or acrosyringium, representing 0.005-0.01% of all cutaneous tumors. About 20% of EPC will recur and about 20% will metastasize to regional lymph nodes. There is a mortality rate of 67% in patients with lymph node metastases. Although rare, the occurrence of distant metastases has been reported.
We report a case of patient with EPC of the left arm, with axillary nodal involvement and subsequent local relapse, treated by complete lymph node dissection and electrochemotherapy (ECT).
EPC is an unusual tumor to diagnose. Neither chemotherapy nor radiation therapy has been proven to be of clinical benefit in treating metastatic disease. Although in the current case the short follow-up period is a limitation, we consider in the management of EPC a therapeutic approach involving surgery and ECT, because of its aggressive potential for loregional metastatic spread.
Eccrine porocarcinoma (EPC) is a rare type of skin cancer arising from the intraepidermal portion of eccrine sweat glands or acrosyringium, being a primary tumor or, even more common, a malignant transformation of an eccrine poroma (EP), representing 0.005-0.01% of all cutaneous tumors . In Europe, the incidence rate was < 0.28/100,000 . It mainly occurs in the elderly, with equal incidence in both sexes. Approximatively less than 300 cases of EPC have been reported in medical literature since this disease was first described in 1963 [3–12]. About 20% of EPC will recur and about 20% will metastasize to regional lymph nodes . There is a mortality rate of 67% in patients with lymph node metastases . Although rare, the occurrence of distant metastases has been reported .
We report a case of patient with EPC of the left arm with axillary nodal involvement and subsequent local relapse. The etiology, diagnosis, management and prognosis of this disease are discussed, with a brief review of the literature.
EPC is an infrequent cutaneous neoplasm arising from the cells of the acrosyringium with metastatic potential. This tumor may occur de novo or developing from a pre-existing lesion as degenerative progression, and it can manifest clinically as a solitary lesion with non characteristic macroscopic appearance, as an ulcerated nodule or as a plaque, polypoid, or verrucous lesion . The most common location of EPC are the lower limbs, head and neck, trunk, vulva, breast, nail bed and upper extremities . The histological diagnosis can be done on specific microscopic features. In the primary tumor, the malignant cells arise from the intraepidermal portion of the eccrine sweat glands and may be limited to the epidermis or may extend into the dermis. The tumor are asymmetric with cords and lobules of polygonal tumor cell, typically with a cribriform pattern. Nuclear atypia is evident, with frequent mitoses and necrosis. From the lymphatics, the tumor cells can invade the overlying epidermis because of the "epidermotropic" nature of the tumor cells (Pagetoid pattern) [16–18]. Immunohistochemical studies with positive staining using antibodies to various kinds of antigens (human CK, EMA, carcynoembrionic antigen, p53 protein and others) can be done to confirm acrosyringeal differentiation and to support the conclusive diagnosis . The differential diagnosis of EPC is extensive and runs the spectrum of basal cell carcinoma to metastatic adenocarcinoma . Histologic findings predictive of the aggressive clinical course were the evidence of lymphovascular invasion, which is associated with multiple regional cutaneous metastases, the existence of more than 14 mitoses per field and a tumoral depth of more than 7 mm . In our case, the tumor depth was 3.3 mm with mitotic activity of 14 mitoses per 10 high-power fields, and it showed lymphovascular invasion and Pagetoid intraepidermal extension. Both regional and distant metastases are attributed to the tumor's ability to invade the dermal lymphatics. Solid organ metastases are observed in 10% of cases, lymph nodes metastases in 20% of cases, and local recurrence in 20% of cases [5–15]. However the prognosis of this carcinoma seems difficult to establish due to missed follow-up of cases described in the literature and tumor rarity.
The optimum surgical treatment for EPC is wide surgical excision of the primary tumor with broad tumor margins, given the propensity for local recurrences, with curative rates from 70% to 80% of cases [14–18]. Therapeutic lymphadenectomy should be performed in case of lymphadenopathy, while the role of sentinel lymph node biopsy (SLNB) for staging EPC remains unknown, and probably may be reserved in cases of histological aggressiveness or intralymphatic permeation by the primary tumor [16–20]. In our case, tumor cells were detected in the needle aspiration of the left axillary lymph node and an axillary lymphadenectomy was performed.
Electroporation, which can be used to introduce chemotherapeutic drugs directly into cancer cells (electrochemotherapy), has been shown in clinical trials to have a high response rate in treatment of patients with primary or metastatic skin cancers. The procedure is normally well tolerated by patients and can be repeated . It should be considered as an excellent alternative to standard therapies in treatment of locoregional recurrent EPC.
No standard therapeutic protocols for metastatic EPC exist. However, a variety of chemotherapeutics have been used with varying degree of responsiveness. Gonzales-Lopez et al reported a case of a 71-year-old man developing multiple cutaneous and regional lymph node metastases 15 months after surgical excision of the primary tumor, treated with lymphadenectomy, radiotherapy, and oral isotretinoin, subsequently substituted by tegafur, with no evidence of distant metastases after a 5.6-year follow-up .
EPC is an unusual tumor to diagnose. The treatment for the metastatic disease has not been standardized. Its early identification and complete excision gives the best chance of a cure. Neither chemotherapy nor radiation therapy has been proven to be of clinical benefit in treating metastatic disease. Although in the current case the short follow-up period is a limitation, we consider in the management of EPC a therapeutic approach involving surgery and ECT, because of its aggressive potential for loregional metastatic spread.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Wick MR, Goellner JR, Wolfe JT, Su WP: Adnexal carcinomas of the skin. I. Eccrine carcinomas. Cancer. 1985, 56: 1147-1162. 10.1002/1097-0142(19850901)56:5<1147::AID-CNCR2820560532>3.0.CO;2-3.View ArticlePubMedGoogle Scholar
- Rare Care - Surveillance of Rare Cancers in Europe. http://www.rarecare.eu/
- Pinkus H, Mehregan AH: Epidermotropic eccrine carcinoma. A case combining features of eccrine poroma and Paget's dermatosis. Arch Dermatol. 1963, 88: 597-607.View ArticlePubMedGoogle Scholar
- Mehregan AH, Hashimoto K, Rahbari H: Eccrine adenocarcinoma. A clinicopathologic study of 35 cases. Arch Dermatol. 1983, 119: 104-114. 10.1001/archderm.119.2.104.View ArticlePubMedGoogle Scholar
- Robson A, Greene J, Ansari N, Kim B, Seed PT, McKee PH, Calonje E: Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases. Am J Surg Pathol. 2001, 25: 710-720. 10.1097/00000478-200106000-00002.View ArticlePubMedGoogle Scholar
- McMichael AJ, Gay J: Malignant eccrine poroma in an elderly African-American woman. Dermatol Surg. 1999, 25: 733-735. 10.1046/j.1524-4725.1999.99041.x.View ArticlePubMedGoogle Scholar
- Bleier BS, Newman JG, Quon H, Feldman MD, Kent KK, Wenstein GS: Eccrine prorcarcinoma of the nose: case report and review of world literature. Arch Otolaryngol Head Neck Surg. 2006, 132: 215-218. 10.1001/archotol.132.2.215.View ArticlePubMedGoogle Scholar
- Klenzner T, Arapakis I, Kayser G: Eccrine porocarcinoma of the ear mimicking basaloid squamous cell carcinoma. Otolaryngol Head Neck Surg. 2006, 135: 158-160. 10.1016/j.otohns.2005.03.041.View ArticlePubMedGoogle Scholar
- Shiohara J, Koga H, Uhara H, Takata M, Saida T: Eccrine porocarcinoma: clinical and pathological studies of 12 cases. J Dermatol. 2007, 34: 516-522. 10.1111/j.1346-8138.2007.00324.x.View ArticlePubMedGoogle Scholar
- Gerber PA, Schulte KW, Ruzicka T, Bruch-Gerharz D: Eccrine porocarcinoma of the head: an important differential diagnosis in the elderly patient. Dermatology. 2008, 216: 229-233. 10.1159/000112931.View ArticlePubMedGoogle Scholar
- Jain R, Prabhakaran VC, Huilgol SC, Gehling N, James CL, Selva D: Eccrine porocarcinoma of the upper eyelid. Ophthal Plast Reconstr Surg. 2008, 24: 221-223. 10.1097/IOP.0b013e31816e4167.View ArticlePubMedGoogle Scholar
- Mahomed F, Blok J, Grayson W: The suamous variant of eccrine porocarcinoma: a clinicopathological study of 21 cases. J Clin Pathol. 2008, 61: 361-365. 10.1136/jcp.2007.049213.View ArticlePubMedGoogle Scholar
- Vandeweyer E, Renorte C, Musette S, Gilles A: Eccrine porocarcinoma: a case report. Acta Chir Belg. 2006, 106: 121-123.PubMedGoogle Scholar
- Shaw M, McKee PH, Lowe D, Black MM: Malignant eccrine poroma: a study of twenty-sweven cases. Br J Dermatol. 1982, 107: 675-680. 10.1111/j.1365-2133.1982.tb00527.x.View ArticlePubMedGoogle Scholar
- Brown CW, Dy LC: Eccrine porocarcinoma. Dermatol Ther. 2008, 433-438. 10.1111/j.1529-8019.2008.00243.x.Google Scholar
- Gonzales-Lopez MA, Vasquez-Lopez F, Soler T, Gomez-Diez S, Garzia YH, Manjon JA, Lopez-Escobar M, Perez-Oliva N: Metastatic Eccrine Porocarcinoma: a 5.6 year follow-up study of a patient treated with a combined therapeutic protocol. Dermatol Surg. 2003, 29: 1227-1232. 10.1111/j.1524-4725.2003.29393.x.Google Scholar
- De Giorgi V, Sestini S, Massi D, Papi F, Lotti T: Eccrine Porocarcinomna: a rare but sometimes fatal malignant neoplasm. Dermatol Surg. 2007, 33: 374-377. 10.1111/j.1524-4725.2007.33077.x.PubMedGoogle Scholar
- Luz Mde A, Ogata DC, Montenegro MF, Biasi LJ, Ribeiro LC: Eccrine poro carcinoma (malignant eccrine poroma): a series of eight challenging cases. Clinics (Sao Paulo). 2010, 65: 739-742.View ArticleGoogle Scholar
- Goel R, Contos MJ, Wallace ML: Widespread metastatic eccrine porocarcinoma. J Am Acad Dermatol. 2003, 49: 252-254. 10.1016/S0190-9622(03)00444-4.View ArticleGoogle Scholar
- Nouri K, Rivas MP, Pedroso F, Bhatia R, Civantos F: Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinomas of the head and neck. Arch Dermatol. 2004, 140: 1284-10.1001/archderm.140.10.1284-a.View ArticlePubMedGoogle Scholar
- Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, Baldini F, Mosconi M, Soteldo J, Tedeschi I, Passoni C, Pari C, Di Pietro A, Ferrucci PF: Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther. 2010, 23: 651-661. 10.1111/j.1529-8019.2010.01370.x.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.